1. Home
  2. TBPH vs CNDT Comparison

TBPH vs CNDT Comparison

Compare TBPH & CNDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • CNDT
  • Stock Information
  • Founded
  • TBPH 2013
  • CNDT 2016
  • Country
  • TBPH United States
  • CNDT United States
  • Employees
  • TBPH N/A
  • CNDT N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • CNDT Business Services
  • Sector
  • TBPH Health Care
  • CNDT Consumer Discretionary
  • Exchange
  • TBPH Nasdaq
  • CNDT Nasdaq
  • Market Cap
  • TBPH 464.5M
  • CNDT 497.6M
  • IPO Year
  • TBPH N/A
  • CNDT N/A
  • Fundamental
  • Price
  • TBPH $10.77
  • CNDT $2.53
  • Analyst Decision
  • TBPH Buy
  • CNDT
  • Analyst Count
  • TBPH 3
  • CNDT 0
  • Target Price
  • TBPH $11.33
  • CNDT N/A
  • AVG Volume (30 Days)
  • TBPH 379.4K
  • CNDT 1.6M
  • Earning Date
  • TBPH 05-08-2025
  • CNDT 05-07-2025
  • Dividend Yield
  • TBPH N/A
  • CNDT N/A
  • EPS Growth
  • TBPH N/A
  • CNDT N/A
  • EPS
  • TBPH N/A
  • CNDT 1.54
  • Revenue
  • TBPH $65,266,000.00
  • CNDT $3,186,000,000.00
  • Revenue This Year
  • TBPH $51.09
  • CNDT N/A
  • Revenue Next Year
  • TBPH N/A
  • CNDT $2.53
  • P/E Ratio
  • TBPH N/A
  • CNDT $1.65
  • Revenue Growth
  • TBPH 6.11
  • CNDT N/A
  • 52 Week Low
  • TBPH $7.44
  • CNDT $1.90
  • 52 Week High
  • TBPH $11.82
  • CNDT $4.90
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 64.32
  • CNDT 62.76
  • Support Level
  • TBPH $9.10
  • CNDT $2.08
  • Resistance Level
  • TBPH $11.82
  • CNDT $2.58
  • Average True Range (ATR)
  • TBPH 0.39
  • CNDT 0.13
  • MACD
  • TBPH 0.19
  • CNDT 0.04
  • Stochastic Oscillator
  • TBPH 62.23
  • CNDT 88.24

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About CNDT Conduent Incorporated

Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments namely Commercial Industries which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas of which the majority of revenue is generated in the United States.

Share on Social Networks: